Park Place Capital Corp Has $27,000 Stock Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Park Place Capital Corp lowered its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 38.0% in the fourth quarter, HoldingsChannel reports. The fund owned 1,157 shares of the company’s stock after selling 710 shares during the period. Park Place Capital Corp’s holdings in Privia Health Group were worth $27,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of PRVA. BlackRock Inc. boosted its position in Privia Health Group by 201.7% during the 2nd quarter. BlackRock Inc. now owns 13,938,867 shares of the company’s stock worth $363,944,000 after acquiring an additional 9,319,052 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Privia Health Group in the 4th quarter valued at approximately $44,811,000. Millennium Management LLC boosted its holdings in shares of Privia Health Group by 183.8% in the 4th quarter. Millennium Management LLC now owns 2,996,072 shares of the company’s stock valued at $68,041,000 after buying an additional 1,940,218 shares during the last quarter. State Street Corp boosted its holdings in shares of Privia Health Group by 138.0% in the 2nd quarter. State Street Corp now owns 2,979,093 shares of the company’s stock valued at $77,784,000 after buying an additional 1,727,559 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of Privia Health Group by 71.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,780,204 shares of the company’s stock valued at $80,960,000 after buying an additional 1,162,270 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on PRVA shares. Barclays started coverage on Privia Health Group in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $22.00 price objective for the company. Bank of America downgraded Privia Health Group from a “buy” rating to a “neutral” rating and cut their price objective for the company from $27.00 to $21.00 in a report on Thursday, February 22nd. Truist Financial cut their price objective on Privia Health Group from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Jefferies Financial Group started coverage on Privia Health Group in a report on Monday, February 26th. They issued a “buy” rating and a $25.00 price objective for the company. Finally, UBS Group dropped their price target on Privia Health Group from $31.00 to $29.00 and set a “buy” rating on the stock in a research note on Friday, March 1st. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.58.

Insiders Place Their Bets

In other Privia Health Group news, Director William M. Sullivan sold 9,951 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $23.03, for a total transaction of $229,171.53. Following the transaction, the director now owns 5,464,533 shares in the company, valued at approximately $125,848,194.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director William M. Sullivan sold 9,951 shares of the stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $23.03, for a total transaction of $229,171.53. Following the sale, the director now directly owns 5,464,533 shares of the company’s stock, valued at approximately $125,848,194.99. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO David Mountcastle sold 3,933 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $17.77, for a total value of $69,889.41. Following the sale, the chief financial officer now directly owns 262,279 shares in the company, valued at $4,660,697.83. The disclosure for this sale can be found here. Company insiders own 44.80% of the company’s stock.

Privia Health Group Price Performance

PRVA stock opened at $18.57 on Monday. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of 97.74, a PEG ratio of 2.54 and a beta of 0.81. The business’s fifty day moving average price is $20.50 and its two-hundred day moving average price is $21.67. Privia Health Group, Inc. has a fifty-two week low of $17.54 and a fifty-two week high of $30.15.

Privia Health Group (NASDAQ:PRVA) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $440.80 million for the quarter, compared to the consensus estimate of $425.81 million. Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The firm’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.14 EPS. Research analysts expect that Privia Health Group, Inc. will post 0.26 EPS for the current year.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.